The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak
The coronavirus disease 19 (COVID-19) pandemic poses a serious threat to the sustainability of healthcare systems and is currently having a significant effect on living conditions worldwide. No therapeutic agent has yet proven to be effective for the treatment of COVID-19. The management of this dis...
Main Authors: | Marco Canevelli, Giulia Remoli, Federica Trentin, Gabriele Riccardi, Leonardo Tariciotti, Giovanni Risoleo, Antonio Ancidoni, Giuseppe Bruno, Matteo Cesari, Nicola Vanacore, Valeria Raparelli |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2020.552991/full |
Similar Items
-
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
by: Eleonora Aricò, et al.
Published: (2021-09-01) -
How many frailties exist?
by: Matteo Cesari, et al.
Published: (2021-10-01) -
Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer’s Disease: The Paradigmatic Example of CSF
by: Marco Canevelli, et al.
Published: (2019-10-01) -
HORSE-RACING EFFECT AND CLINICAL TRIALS IN OLDER PERSONS
by: Matteo eCesari, et al.
Published: (2014-07-01) -
Editorial: Dementia, Frailty and Aging
by: Wee-Shiong Lim, et al.
Published: (2018-05-01)